COVID-19 vaccines based on mRNA, adenovirus vector, or inactivated virus platforms and validated for use in humans [4] also induce SARS-CoV-2-specific CD8+ and CD4+ T-cell responses [14,16] that resemble the timing of responses following natural infection [17,18]. The gene discussed is CD8A; the disease is COVID-19.